Washington, D.C., November 19, 2026.- The Pan American Health Organization (PAHO/WHO) is supporting the Medicines Patent Pool (MPP) in promoting a call for expressions of interest aimed at pharmaceutical manufacturers in Latin America and the Caribbean to participate in the technology transfer, production, and expanded access to baloxavir marboxil, an innovative antiviral treatment for pandemic and seasonal influenza. The MPP call seeks to select an additional manufacturer in the region.
Geographically diversified manufacturing capacity helps strengthen supply chain resilience and improve the availability of health technologies, both to meet public health needs and to respond to health emergencies. In this context, the incorporation of new manufacturers from the Region into the production of baloxavir marboxil represents an opportunity to strengthen preparedness for future influenza pandemics. This initiative aligns with the policy to increase manufacturing capacity and access to medicines and health technologies, approved by PAHO Member States in 2021 (CD59.R3).
The MPP call is being conducted under the voluntary licensing agreement between MPP and Roche, which aims to expand access to this medicine in 129 low- and middle-income countries, strengthen regional manufacturing capacity, and contribute to preparedness and response for future pandemics.
About the medicine
Baloxavir marboxil (Xofluza®) is a single-dose oral antiviral treatment used for influenza. The medicine acts in the early stages of infection, reducing the duration of illness and limiting virus transmission. It has also demonstrated efficacy against strains resistant to other classes of antivirals and is included in the World Health Organization (WHO) clinical guidelines for influenza.
Informational Webinar
On December 1, 2026, PAHO and MPP will host a webinar for interested manufacturers, presenting the objectives of the call, participation requirements, and the process for submitting expressions of interest, including a demonstration of the application portal.
Time: 15:00 CET | 11:00 Argentina and Brazil | 09:00 Colombia, Panama, and Washington, D.C. | 08:00 Mexico.
How to participate?
- The call is open to pharmaceutical manufacturers in Latin America and the Caribbean with relevant capabilities for the development, production, and supply of medicines.
- Interested parties can review the call details and requirements and submit their expression of interest through the MPP portal.
Deadline for applications: December 15, 2026, at 23:59 (Central European Time).
MPP is responsible for managing the call and the selection process for the manufacturer that will receive the sublicense.
About the Medicines Patent Pool The Medicines Patent Pool (MPP) is a United Nations-backed public health organization that works to expand access to innovative medicines and health technologies in low- and middle-income countries through licensing agreements and technology transfer mechanisms.
